Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

influenza vaccine

- PMLiVE

Merck and Ridgeback’s oral antiviral halves COVID-19 risk of hospitalisation or death

The phase 3 study shows the risk was halved compared to placebo for patients with mild or moderate COVID-19

- PMLiVE

Sanofi refocuses COVID-19 efforts away from mRNA

Trial data validates Sanofi’s mRNA and lipid nanoparticle platform but the company will not pursue its own mRNA COVID-19 vaccine

- PMLiVE

COVID-19 Pfizer/BioNTech booster approved by FDA and CDC

The plan to offer Americans a third, booster shot of the Pfizer/BioNTech COVID-19 vaccine has finally been waved through by the FDA and CDC

- PMLiVE

New data from Moderna supports COVID boosters

Waning immunity from its mRNA jab “support benefit” of a booster shot, says Moderna, while international scientists publish plea for evidence over politics

EU flag

EU “still interested” in Valneva COVID vaccine despite UK snub

Negotiations between Valneva and the EU are “ongoing and advanced”, with its vaccine candidate VLA2001 touted as a potential booster shot in France

regeneron headquarters

US orders 1.4 million more doses of Regeneron antibody cocktail

The new $2.9bn order increases the amount of Regeneron’s anti-COVID REGEN-COV purchased by the US government to nearly 3 million doses

- PMLiVE

UK announces COVID boosters for a “bumpy winter” ahead

A single shot of Pfizer’s COVID-19 vaccine will be offered to 30 million people in the UK including those 50 or over and frontline health and social care workers

- PMLiVE

Valneva shares fall as UK cancels COVID-19 vaccine order

The UK government has cancelled a supply agreement for French vaccine maker Valneva’s COVID candidate VLA2001 over an alleged breach of obligations.

- PMLiVE

Pfizer starts RSV trial ahead of winter season

A vaccine against the common respiratory syncytial virus could be available soon, as Pfizer joins GSK and J&J in launching phase 3 trials

- PMLiVE

FDA’s director and deputy director of its Office of Vaccines Research & Review resign

The departure of director Marion Gruber and deputy director Philip Krause is unexpected

- PMLiVE

GSK/SK bioscience COVID-19 vaccine to enter phase 3 trial

The study will be one of the first global phase 3 trials to compare two different COVID-19 vaccine candidates

- PMLiVE

Pfizer/BioNTech file for FDA approval for COVID-19 booster jab

New data shows third dose boosts antibodies by more than three times

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links